Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 206

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 206
---
10% of the aggregate number of outstanding shares of our common stock from the first day of the preceding calendar yearto the first day of the current calendar year or such lesser number as determined by our board of directors. On May 15, 2024 at the Company’s 2024 Annual Meeting of Stockholders, an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the Plan to 10,206was approved. F-18 REVELATION BIOSCIENCES, INC.
Notes to the Consolidated Financial Statements 9. Stock-Based Compensation(cont.)

Under the 2021 Plan, stock
options and stock appreciation rights are granted at exercise prices determined by the Board of Directors which cannot be less than %
of the estimated fair market value of the common stock on the grant date. Incentive stock options granted to any stockholders holding
10% or more of the Company’s equity cannot be granted with an exercise price of less than % of the estimated fair market value
of the common stock on the grant date and such options are not exercisable after five years from the grant date.

As of December 31, 2024,
there were shares available for future grants under the 2021 Plan.

Restricted Stock Units

As of December 31, 2024
and December 31, 2023, the Company has a total of Rollover RSU awards for shares of common stock outstanding, respectively. As
of December 31, 2024, Rollover RSU awards have fully vested but are unissued and no Rollover RSU awards have been forfeited. Each
Rollover RSU award converts to one share of common stock.

Stock Options

The Company has granted stock
options Stock options have a maximum term of or years.

The activity related to stock
options during the year ended December 31, 2024 is summarized as follows:

|                                  |     | Shares |    |     | Weighted- 
 average   
 Exercise  
 Price     |          |     | Weighted-   
 average     
 Remaining   
 Contractual 
 Term        
 (Years)     |     |
|:---------------------------------|:----|:-------|---:|:----|:----------|---------:|:----|:------------|----:|
| Outstanding at December 31, 2023 |     |        | 64 |     | $         | 3,555.83 |     |             |     |
| Granted                          |